At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
CD3/CD28biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant
In Brief
A Phase 2 clinical trial evaluating CD3/CD28 for Multiple Myeloma. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense Id-specific immunity than non Id-KLH primed CD3/CD28 activated autologous lymphocytes. There will be 2 arms in the study, one receiving a DLI with non Id-KLH vaccine and one receiving aDLI with Id-KLH vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedSep 2011
Primary CompletionJun 2016
Study CompletionDec 2017
TodayJul 2026
First PostedSep 1, 2011
Enrollment StartAug 1, 2011
Primary CompletionJun 1, 2016
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.8 years ago
Interventions
CD3/CD28biological
CD3/CD28 activated autologous lymphocytes intravenously